

# MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/M46A166BC5F3EN.html>

Date: September 2021

Pages: 59

Price: US\$ 125.00 (Single User License)

ID: M46A166BC5F3EN

## Abstracts

MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

MediGene AG (MediGene) is a biotechnology company which develops innovative immunotherapies to treat cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB's), for isolation of antibodies for monitoring and tracking of TCR-Ts. The company has operational presence in the US and Europe. MediGene is headquartered in Planegg, Germany.

### MediGene AG Key Recent Developments

Aug 12,2021: MediGene provides Q2 update and 6m report 2021

May 11,2021: MediGene provides Q1 2021 update

May 10,2021: MediGene presents new data on components of solid cancer TCR-T therapies at cimt

Mar 18,2021: MediGene: Change in the executive management board

Jan 13,2021: MediGene expands patent protection of its technologies in key markets, the USA and Europe

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios

and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

MediGene AG - Key Facts  
MediGene AG - Key Employees  
MediGene AG - Key Employee Biographies  
MediGene AG - Major Products and Services  
MediGene AG - History  
MediGene AG - Company Statement  
MediGene AG - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
MediGene AG - Business Description  
Business Segment: Immunotherapies (core business)  
Overview  
Performance  
Business Segment: Other Products (non-core business)  
Overview  
Performance  
Geographical Segment: Asia  
Performance  
Geographical Segment: Europe  
Performance  
Geographical Segment: Others  
Performance  
Geographical Segment: The US  
Performance  
MediGene AG - Corporate Strategy  
MediGene AG - SWOT Analysis  
SWOT Analysis - Overview  
MediGene AG - Strengths  
MediGene AG - Weaknesses  
MediGene AG - Opportunities  
MediGene AG - Threats

MediGene AG - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

MediGene AG, Recent Deals Summary

### **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Aug 12, 2021: Medigene provides Q2 update and 6m report 2021

May 11, 2021: Medigene provides Q1 2021 update

May 10, 2021: Medigene presents new data on components of solid cancer TCR-T therapies at cimt

Mar 18, 2021: Medige: Change in the executive management board

Jan 13, 2021: Medigene expands patent protection of its technologies in key markets, the USA and Europe

Dec 16, 2020: DR. Anthony Man appointed to Supervisory Board

Nov 12, 2020: Medigene provides Q3 2020 update

Aug 07, 2020: Medigene provides Q2 update and 6M report 2020

Jun 22, 2020: Medigene’s PD1-41BB switch receptor enhances TCR-T cell activity towards solid tumors

May 14, 2020: Medigene provides Q1 2020 update

### **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

## Disclaimer

## List Of Tables

### LIST OF TABLES

MediGene AG, Key Facts  
MediGene AG, Key Employees  
MediGene AG, Key Employee Biographies  
MediGene AG, Major Products and Services  
MediGene AG, History  
MediGene AG, Subsidiaries  
MediGene AG, Key Competitors  
MediGene AG, Ratios based on current share price  
MediGene AG, Annual Ratios  
MediGene AG, Annual Ratios (Cont...1)  
MediGene AG, Annual Ratios (Cont...2)  
MediGene AG, Interim Ratios  
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
MediGene AG, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios



## List Of Figures

### LIST OF FIGURES

MediGene AG, Performance Chart (2016 - 2020)

MediGene AG, Ratio Charts

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

## I would like to order

Product name: MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/M46A166BC5F3EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M46A166BC5F3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970